August 11, 2016
___________________________________________________________________
The Drug Enforcement Administration (DEA) announced this week that it
will lift restrictions on cannabis research as soon as August 11, 2016.
This policy change will open the door for broader study of the drug,
increasing the availability of marijuana to researchers, including those
looking at its use in people with HIV. The administration did not,
however, change marijuana's classification as a Schedule I "dangerous" drug.
The new policy could lead to increased support for medical marijuana and perhaps to a reclassification of the drug in the future.
"HIV specialists have been hearing about the medical use of marijuana even longer than we've had effective antiretroviral therapy," Paul E. Sax, M.D. noted earlier this year in Journal Watch. "Initially touted as an appetite stimulant for HIV-related anorexia and weight loss, and as palliative therapy to ease the pain of death and dying, it gained further use in the mid-1990s when early HIV-related combination regimens caused so much nausea," he recalled.
Sax noted that Donald Abrams, M.D., of the University of California San Francisco had overcome obstacles to marijuana research to find that five days of smoking the herb was superior to placebo in 50 people with HIV-related peripheral neuropathy. In a more recent assessment, marijuana use was also tied to lower insulin resistance risk in people coinfected with HIV and hepatitis C in France. And an animal study several years ago made the tantalizing observation that tetrahydrocannabinol (THC), the main active ingredient in marijuana, seemed to decrease cellular damage in gut tissue, which could lead to approaches that limit the spread of HIV in the body.
Medical uses of marijuana, along with reclassification and legalization of the drug, remain controversial. According to some experts, this policy change is unnecessary, and according to others, it does not go far enough. Earlier in 2016, the DEA reported that cannabis would likely be reclassified to a Schedule II drug -- drugs with a high potential for abuse that may lead to severe psychological or physical dependence -- but that measure has not yet occurred. Under the new policy, researchers will need approval from the FDA and DEA to conduct medical marijuana studies.
Diane Domina is a senior content producer at Remedy Health Media, LLC. She writes the Daily Dose for HealthCentral and is the editorial director at HealthCommunities. Her goal is to contribute to a valuable, trustworthy, and informative experience for people who are searching for health information online.
Additional reporting was provided by JD Davids.
Copyright © 2016 Remedy Health Media, LLC. All rights reserved.
Read more articles here: The Body
__________________________________________________________________
Related Stories
| Marijuana May Have Potential as an HIV Treatment | ||||
| Can I Smoke Marijuana While on HIV Meds? | ||||
| More News and Viewpoints on Medical Marijuana |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.